Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette-Guérin therapy for bladder cancer.
Intravesical application of bacillus of Calmette-Guérin (BCG) has proved to be an effective form of treatment for some stages of bladder cancer. Infrequent, serious complications of this treatment have become apparent as its use has become more widespread. We report a case of Mycobacterium bovis mycotic abdominal aortic aneurysm and a case of M. bovis mycobacteremia that developed as complications of intravesical BCG therapy. These cases are discussed in the context of a review of reported complications of intravesical BCG therapy and a review of measures currently advocated to prevent them.
Hellinger
W C
WC
Division of Infectious Diseases, Mayo Clinic Jacksonville, FL 32224, USA.
Oldenburg
W A
WA
Alvarez
S
S
D000283:Administration, Intravesical; D000368:Aged; D017544:Aortic Aneurysm, Abdominal / Q000209:etiology*; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016470:Bacteremia / Q000209:etiology*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D008297:Male; D009164:Mycobacterium Infections / Q000209:etiology*; D009163:Mycobacterium bovis; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine